OncoMatch/Clinical Trials/NCT03649880

Feasibility of FMISO in Brain Tumors

Is NCT03649880 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies ¹⁸F-Fluoromisonidazole for malignant brain neoplasm.

Phase 2RecruitingOHSU Knight Cancer InstituteNCT03649880Data as of May 2026

Treatment: ¹⁸F-Fluoromisonidazole — This phase II trial studies how well ¹⁸F- fluoromisonidazole (FMISO) works with positron emission tomography (PET)/magnetic resonance imaging (MRI) in assessing participants with malignant (cancerous) brain tumors. FMISO provides information about the oxygen levels in a tumor, which may affect how the tumor behaves. PET/MRI imaging produces images of the brain and how the body functions. FMISO PET/MRI may help investigators see how much oxygen is getting in the brain tumors.

Check if I qualify

Extracted eligibility criteria

Cancer type

Glioblastoma

Lab requirements

Kidney function

gfr >= 45 ml/min/1.73 m^2

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

OHSU Knight Cancer Institute · Portland, Oregon

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify